News-Medical.Net January 25, 2026
An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing mortality gap faced by people with serious mental illnesses by tackling cardiovascular risk and metabolic disease head-on.
A recent editorial published in the journal Expert Opinion on Pharmacotherapy discussed that glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) may potentially transform health outcomes for individuals with serious mental illnesses (SMIs). The authors emphasized that these agents are most likely to improve outcomes by addressing the cardiometabolic drivers of excess morbidity and mortality rather than replacing established psychiatric treatments.
Development and Expanding Indications of GLP-1 Receptor Agonists
In 2005, the United States (US) Food and Drug Administration approved the first GLP-1 receptor agonist, exenatide, for the...
Today's Sponsors
Today's Sponsor